Bristol-Myers Squibb reports strong growth in Q3 2013

Bristol-Myers Squibb has published its financial results for the third quarter of 2013, during which it experienced a nine percent year-on-year rise in net sales.

The company's net sales total for the period came to $4.06 billion (2.51 billion pounds), thanks to the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, all of which experienced double-digit gains.

During the quarter, the firm also presented important clinical data for its immuno-oncology pipeline and key cardiovascular outcomes data for Onglyza, while agreeing a ten-year alliance with Samsung BioLogics.

For the full year, a GAAP earnings per share guidance range of $1.41 to $1.49 has been confirmed.

Lamberto Andreotti, chief executive officer at Bristol-Myers Squibb, said: "As we continue to execute against our strategy today, we remain focused on investing in the meaningful opportunities that will drive the long-term growth of our company."

Earlier this month, the company announced the launch of Partnering for Cure, a new initiative to support education and research in the field of chronic viral diseases.